# CELC PDUFA Calendar: FDA Decision Dates & Catalyst Timeline

Canonical URL: https://biopharmsignal.com/pdufa-calendar/CELC
Company: Celcuity

BioPharmSignal tracks active PDUFA and FDA decision milestones associated with CELC.

## CELC PDUFA Milestones

- 2026-07-17 — PDUFA — FDA approved REVTORPYK regimens. FDA approved REVTORPYK with fulvestrant, with or without palbociclib, for the specified HR-positive, HER2-negative, PIK3CA w...
  Company: Celcuity
  Source: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally
  Event detail: https://biopharmsignal.com/pdufa-calendar/CELC/gedatolisib-pik3ca-wild-type-advanced-breast-cancer.md
  Month page: https://biopharmsignal.com/pdufa-calendar/2026/july (July 2026)

## Related Pages

- Company page: https://biopharmsignal.com/company/CELC
- Interactive PDUFA Calendar: https://biopharmsignal.com/pdufa-calendar

## FAQ

### What does the CELC PDUFA calendar show?

It shows active PDUFA and FDA decision milestones associated with CELC, including decision dates, application stage, and summary details when available.
### Where can I find more context for CELC?

Use the BioPharmSignal company page for CELC to read related news, stock data, sector context, and company-specific updates.
### Are these dates investment advice?

No. PDUFA dates are research inputs, not investment recommendations. Always review primary sources and understand the clinical and regulatory context.